INNOVATE Corp. (VATE)

NYSE: VATE · Real-Time Price · USD
18.98
+1.83 (10.67%)
Jun 5, 2026, 4:00 PM EDT - Market closed
Market Cap258.92M +240.2%
Revenue (ttm)1.34B +25.4%
Net Income-56.40M
EPS-4.25
Shares Out 13.64M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume127,047
Open17.15
Previous Close17.15
Day's Range17.03 - 19.59
52-Week Range3.75 - 19.59
Beta2.34
Analystsn/a
Price Targetn/a
Earnings DateMay 14, 2026

About VATE

INNOVATE Corp., through its subsidiaries, operates in infrastructure, life sciences, and spectrum areas in the United States. The company operates through the Infrastructure, Life Sciences, and Spectrum segments. The Infrastructure segment provides industrial construction, structural steel, and facility maintenance services, such as fabrication and erection of structural steel and heavy steel plate services, and large-diameter water pipes and water storage tanks; fabrication of trusses and girders; 3-D building information modeling and detailin... [Read more]

IPO Date Nov 7, 1996
Employees 3,738
Stock Exchange NYSE
Ticker Symbol VATE
Full Company Profile

Financial Performance

In 2025, INNOVATE's revenue was $1.25 billion, an increase of 12.55% compared to the previous year's $1.11 billion. Losses were -$64.00 million, 78.8% more than in 2024.

Financial Statements

News

INNOVATE Announces Successful Closing of Broadcasting Refinancing and Agrees to Partial Sale of Broadcasting

NEW YORK, June 01, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that HC2 Broadcasting Holdings Inc. (“Broadcasting”) closed on a refinancing trans...

6 days ago - GlobeNewsWire

INNOVATE Earnings Call Transcript: Q1 2026

Q1 2026 saw 33% revenue growth to $364.8M and improved adjusted EBITDA, driven by infrastructure gains, while Life Sciences and Spectrum faced revenue declines. Net loss narrowed, cash increased, and backlog remains strong, supporting a positive outlook.

24 days ago - Transcripts

INNOVATE Slides: Q1 2026

INNOVATE has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 14, 2026.

24 days ago - Filings

INNOVATE Earnings release: Q1 2026

INNOVATE released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.

24 days ago - Filings

INNOVATE Quarterly report: Q1 2026

INNOVATE has published its Q1 2026 quarterly earnings report on May 14, 2026.

24 days ago - Filings

INNOVATE Corp. Announces First Quarter 2026 Results

- Infrastructure: Strong first quarter results with revenue of  $357.9 million - Life Sciences: MediBeacon receives the CE mark for the Transdermal GFR Monitor and Reusable Sensor - Spectrum: More tha...

24 days ago - GlobeNewsWire

INNOVATE Proxy statement: Proxy filing

INNOVATE filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.

5 weeks ago - Filings

INNOVATE Proxy statement: Proxy filing

INNOVATE filed a proxy statement on April 28, 2026, providing details for shareholder voting and corporate governance matters.

5 weeks ago - Filings

INNOVATE Corp. to Report First Quarter 2026 Results on May 14th

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the first quarter 2026 on Thursday...

5 weeks ago - GlobeNewsWire

INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

NEW YORK, April 06, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that DBM Global Inc. (“DBMG”), a family of companies providing fully integrated s...

2 months ago - GlobeNewsWire

MediBeacon® Transdermal GFR Monitor and Reusable Sensor Receive CE Mark Under European Medical Device Regulation

NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in...

2 months ago - GlobeNewsWire

INNOVATE Earnings Call Transcript: Q4 2025

Fourth quarter revenue surged 61.7% year-over-year, driven by infrastructure, while net loss narrowed. Life sciences and spectrum segments faced headwinds, but regulatory wins and backlog growth position the company for 2026 expansion.

2 months ago - Transcripts

INNOVATE Annual report: Q4 2025

INNOVATE has published its Q4 2025 annual report on March 26, 2026.

2 months ago - Filings

INNOVATE Earnings release: Q4 2025

INNOVATE released its Q4 2025 earnings on March 26, 2026, summarizing the period's financial results.

2 months ago - Filings

INNOVATE Slides: Q4 2025

INNOVATE has posted slides in relation to its Q4 2025 quarterly earnings report, which was published on March 26, 2026.

2 months ago - Filings

INNOVATE Corp. Announces Fourth Quarter and Full Year 2025 Results

- Infrastructure: NYC and Western markets continue to demonstrate positive project momentum - - Life Sciences: R2 Secures 600‑System Commitment in China - - Spectrum: Recent network launches set to de...

2 months ago - GlobeNewsWire

INNOVATE Corp. to Report Fourth Quarter and Full Year 2025 Results on March 26th

NEW YORK, March 16, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that it will release its financial results for the fourth quarter and full year 2...

2 months ago - GlobeNewsWire

Transdermal GFR Article Recognized as One of Five 2025 Editors' Choice Articles by Journal of the American Society of Nephrology (JASN)

NEW YORK, Feb. 10, 2026 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...

4 months ago - GlobeNewsWire

INNOVATE Corp.’s DBM Global to pay $1.30 per share dividend

INNOVATE Corp. (VATE) announced that DBM Global, an operating subsidiary of INNOVATE, will pay a cash dividend of approximately $5M, or $1.30 per share, on February 24, 2026 to DBMG’s…

4 months ago - TheFly

INNOVATE announces MediBeacon received approval for TGFRTM System

INNOVATE announced that MediBeacon, in which INNOVATE owns a 44.7% equity interest, has received approval from the U.S. Food and Drug Administration, FDA, for the next generation MediBeacon TGFRTM Sys...

6 months ago - TheFly

MediBeacon® Next Generation TGFR™ System Receives FDA Approval

NEW YORK, Dec. 16, 2025 (GLOBE NEWSWIRE) -- INNOVATE Corp. (NYSE: VATE) (“INNOVATE” or the “Company”) announced today that MediBeacon Inc. (“MediBeacon”), a medical technology company specializing in ...

6 months ago - GlobeNewsWire

INNOVATE Earnings Call Transcript: Q3 2025

Q3 2025 revenue rose 43% year-over-year to $347.1M, led by infrastructure and life sciences growth, while net loss narrowed. DBM Global's backlog and R2's international sales surged, and MediBeacon secured key regulatory approval in China.

7 months ago - Transcripts

INNOVATE Earnings release: Q3 2025

INNOVATE released its Q3 2025 earnings on November 12, 2025, summarizing the period's financial results.

7 months ago - Filings

INNOVATE Quarterly report: Q3 2025

INNOVATE has published its Q3 2025 quarterly earnings report on November 12, 2025.

7 months ago - Filings

INNOVATE Slides: Q3 2025

INNOVATE has posted slides in relation to its Q3 2025 quarterly earnings report, which was published on November 12, 2025.

7 months ago - Filings